Background {#Sec1}
==========

The onus on clear research reporting and indeed optimal yield from randomised trials has been highlighted increasingly in recent years with much research now accepted as being suboptimal with ensuing financial and systemic waste \[[@CR1]\]. Among the more pressing shortcomings are failure to consider questions of relevance to clinicians and patients, inappropriate design and methods, publication bias, and biased and incomplete reporting \[[@CR2]\].

Accepted prerequisites for randomised trials are the existence of genuine uncertainty concerning the relative merits of competing interventions and appropriate design to permit meaningful answers \[[@CR3]\]. An appreciation of the existence of previous research is therefore necessary to avoid unnecessary duplication, and due consideration of the evidence base is important in informing appropriate design and methodology. Notwithstanding this, replication of previous studies may be justified in confirming previous results or in an effort to assess the generalizability of novel findings \[[@CR4]\].

It is accepted that relevant research, including systematic reviews where they exist and randomised trials, should be cited in the introduction section of reports of randomised controlled trials (RCTs) \[[@CR3]\]. There are also growing concerns in relation to publication bias and selective outcome reporting in biomedical journals \[[@CR5], [@CR6]\]. Consequently, in recent years there has been an increasing drive to publish research protocols both to prevent unwanted duplication and to mitigate the risk of reporting bias \[[@CR7]\]. The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines \[[@CR7]\] aim to improve the reporting and quality of clinical trial protocols and incorporate a checklist of recommended items to include in the trial protocol \[[@CR7]\]. Within the SPIRIT guidelines, citation of prior research in the introduction section and justification of randomised trials on the basis of gaps in the underlying evidence base are advocated \[[@CR7]\]. The SPIRIT checklist strongly recommends placing: "The trial in the context of available evidence, it is strongly recommended that an up-to-date systematic review of relevant studies be summarised and cited in the protocol."

Previous research has addressed the issue of recognition of prior studies in stimulating or informing further research \[[@CR8]--[@CR10]\]. Robinson and Goodman \[[@CR11]\] in an analysis of RCTs contributing to meta-analyses identified that less than one quarter of relevant trials had been cited. Similarly, Clarke and Hopewell \[[@CR10]\] in a survey of five leading medical journals reported sparse referencing of systematic reviews either in the introduction or discussion sections. Consequently, randomised trial reports may routinely fail to place research findings in appropriate context potentially hampering the end user's ability to reach balanced, informed decisions about important healthcare interventions. Failure to consider the available and latest evidence may jeopardize the justification for new randomised research on ethical grounds.

To our knowledge no studies exist assessing the justification for randomised trials based on the available evidence at the protocol stage and in accordance with SPIRIT. The aim of this meta-epidemiological study was to assess the extent to which published protocols of randomised trials adhere to SPIRIT and include an updated systematic review to inform the trial design in the background or rationale sections.

Methods {#Sec2}
=======

Sample {#Sec3}
------

All published protocols of planned randomised controlled trials (RCTs) were identified over a 1-month period (December 2015) indexed in PubMed based on a defined search strategy (Table [1](#Tab1){ref-type="table"}).Table 1Search strategy for protocol selection"protocol\[ti\] AND random\*"Filter for "randomised trials" and time range1. randomised controlled trial \[pt\] OR controlled randomised trial \[pt\] OR randomised \[tiab\] OR randomised \[tiab\] OR placebo \[tiab\] OR randomly \[tiab\] OR trial \[tiab\]2. protocol \[tiab\]3. systematic review OR meta-analysis \[ti\] OR meta analysis \[ti\] OR review \[ti\] OR Review \[pt\] OR Meta-Analysis \[pt\] OR Comment \[pt\] OR Letter \[pt\] OR Editorial \[pt\] OR News \[pt\]4. \#1 AND \#2 NOT \#3

Data extraction {#Sec4}
---------------

Titles and abstracts were screened by one author (NP) in order to select all eligible publications. The selected citations were entered in Endnote reference management software and the corresponding full texts were retrieved for further evaluation. The criteria for defining a report as a "randomised controlled trial protocol" were as follows:Document describing the objectives, design, methodology, statistical considerations, and organisation of a clinical trial including justification and rationale for the trial.Cochrane definition of a trial as randomised: "the individuals (or other units) followed in the trial were assigned prospectively to one of two (or more) alternative forms of health care using random allocation."

The following information was extracted in duplicate by two authors (NP, PSF) from each eligible protocol: title, first author name, number of authors, country and geographic region (i.e. Europe, Americas, Asia, Other) of first author, details of registration, funding, number of trial sites, trial design, funding type, conflict of interest, and data sharing. Following the SPIRIT recommendation within the introduction section the research context used to inform or justify the trial was assessed in one of six ways \[[@CR12]\]:randomised trial is the first to address the questionupdated systematic review was used to inform trial designsystematic review and new trials (published since the systematic review was published) were used to inform trial designprevious systematic review was discussed but was not used in trial designreferences to other randomised trialsno references to other randomised trials or claim to be the first trial

Data analysis {#Sec5}
-------------

Data were independently extracted by two investigators and entered on pre-piloted standardized forms for the eligible protocols. Initial calibration was performed between the two researchers on ten articles. Disagreements were resolved by discussion or, if necessary, with adjudication by a third reviewer and a consensus was reached for all protocols. Descriptive statistics were undertaken and data were tabulated with respect to selected protocol characteristics with the use of STATA® version 14.1 software (Stata Corporation, College Station, TX, USA).

Results {#Sec6}
=======

The PubMed search identified 411 records, 310 of which were excluded as they did not satisfy the inclusion criteria resulting in 101 protocols suitable for full data extraction (Fig. [1](#Fig1){ref-type="fig"}). The Additional file [1](#MOESM1){ref-type="media"} includes the raw data extracted. A variety of medical conditions were considered in the selected protocols (Table [2](#Tab2){ref-type="table"}). The majority of studies were undertaken in multiple centres (84.2%). In terms of geographic region, the highest percentage of studies was carried out in Europe (54.5%; Table [2](#Tab2){ref-type="table"}). Most proposed trials were parallel-group (*n* = 74; 73.3%), while 9.9% (*n* = 10) were cluster designs. The vast majority of studies reported funding (94.1%) with non-industry funding in isolation in 82.2%. Conflict of interest statements were made in the vast majority of protocols (*n* = 96; 95.0%), with the majority having no conflicts to declare (*n* = 77; 76.2%). No commitment to data sharing was made in the majority of protocols (*n* = 93, 92.0%), 7% (*n* = 7) reported that data will be available upon request and only one (1%) protocol indicated the data repository.Fig. 1RCT protocol selection flow diagram Table 2Distribution of demographic variables within the protocols assessed (*n* = 101)Characteristics of assessed protocolsTotalN (101)%Journal Annals of Translational Medicine11.0 BMC umbrella journals2322.7 BMJ Open1514.8 Clinical and Translational Allergy11.0 Contemporary Clinical Trials44.0 Danish Medical Journal11.0 Implementation Science: IS11.0 JAMA Surgery11.0 JMIR Research Protocols22.0 Journal of Advanced Nursing33.0 Journal of Diabetes Science and Technology11.0 Nutrients11.0 Reproductive Health11.0 Springer Plus11.0 The Journal of Cardiovascular Nursing11.0 Trials4443.5Subject Behavioural4948.5 Biological or vaccine11.0 Dietary supplement65.9 Drugs1817.8 Surgery or procedure1413.9 Other1312.9No. centres (according to authors' affiliations) Multi-centre8584.2 Single-centre1615.8Continent of authorship America1918.8 Europe5554.5 Asia and other2726.7No. sites (based on trial conduct) Multiple5251.5 Single4948.5Trial design Parallel7473.3 Cluster109.9 Non-inferiority55.0 Superiority22.0 Other (or mixed-type designs)109.8Type of funding Non-industry8382.2 Part industry54.0 Industry76.9 None/unknown65.9Conflict of interest No7776.2 Yes1918.8 Not described44.0 Unclear11.0Data sharing Data upon request77.0 Data stored in central repository11.0 No information provided9392.0Total101100.0

In terms of citation of relevant research (Table [3](#Tab3){ref-type="table"}), reference to a previous systematic review with additional randomised trials was found in 9.9% (95% CI: 4.9, 17.5) (*n* = 10) of protocols and without additional trials was alluded to in 30.7% (95% CI: 21.9, 40.7) (*n* = 31). A randomised controlled trial was not cited in 10.9% (95% CI: 5.6, 18.7) (*n* = 11), while in 8.9% (95% CI: 4.2, 16.2) (*n* = 9) of the protocols a systematic review was cited but did not inform trial design. Of the cited systematic reviews (*n* = 41), used to inform trial design, 41.5% (*n* = 17) were Cochrane reviews.Table 3Distribution of protocol characteristics in terms of citation of relevant research (*n* = 101)Protocol characteristicsTotal (*n* = 101)N%95% CIClaims that randomised trial is the first to address the question1817.810.9, 26.7Contains an updated systematic review used to inform trial design3130.721.9, 40.7Contains systematic review and new trials (published since the systematic review was published) that were used to inform trial design109.94.9, 17.5Previous systematic review discussed but not used in trial design98.94.2, 16.2Contains references to other randomised trials2221.814.2, 31.1Does not contain references to other randomised trials or claim to be the first trial1110.95.6, 18.7

From the 101 included protocols 89 of those were published in journals endorsing the SPIRIT guidelines.

Discussion {#Sec7}
==========

The CONSORT statement has stipulated that findings from a randomised trial should be placed in the context of the "totality of the available evidence" \[[@CR3]\]. Similarly, when designing a new study it is important that the setting and methodology is informed by previous research. This cross-sectional analysis is the first to assess the citation of high-level research, including both systematic reviews and randomised controlled trials, in reports of published protocols of planned randomised trials. Overall, 41% of the protocols cited a systematic review or a randomised trial that was used to inform trial design.

Previous analyses of reports of randomised trials have indicated that systematic reviews are infrequently cited in reports of randomised trials with sequential audits of trials published in leading medical journals alluding to failure to refer to systematic reviews in 24% of reports in 1997, 10% in 2001, 33% in 2005, 46% in 2009 and 39% in 2012 \[[@CR8]--[@CR10]\]. This finding has arisen despite the pervasion of systematic reviews with in excess of 5000 full Cochrane reviews now published in the Cochrane Database of Systematic Reviews \[[@CR13]\] and several thousand more systematic reviews published on an annual basis \[[@CR14]\]. Our study indicates that trial justification based on systematic reviews and randomised trials at the protocol level is slightly higher compared to published trials and this finding is encouraging, despite the potential imprecision in obtaining these higher values reflected by the wide confidence intervals. Reasons for this are unclear at this stage but it could be speculated that the utility of systematic reviews has improved over time, that a greater onus on trial justification exists at the protocol stage with funding agencies placing an emphasis on evidence of a recent systematic review to justify further clinical research. However, this is the first study to assess this and further research may be required to confirm this pattern within research protocols.

The SPIRIT guidelines were developed in response to inadequate description of trial details such as outcomes and interventions, but also due to unclear description of trial methodology \[[@CR7]\]. These shortcomings may prompt protocol amendments, might hamper trial conduct and can ultimately lead to inadequate reporting \[[@CR15]\]. Moreover, it is important that previous research is considered at the design stages to avoid unnecessary duplication, to inform trial design in order to maximize the yield from expensive and lengthy randomised studies \[[@CR1]\]. Where genuine uncertainty concerning the effectiveness of an intervention is lacking, undertaking such a trial is also considered unethical. It is therefore recommended both within the SPIRIT and CONSORT statements that relevant randomised trials and systematic reviews are identified. It is accepted, however, that compliance with established reporting and conduct guidelines is suboptimal throughout the biomedical literature \[[@CR16]\]. While meta-epidemiological studies focusing on compliance with SPIRIT have not yet been reported, the present investigation does report some encouraging results.

A potential limitation of the present study is the possibility that there may not have been relevant trials or systematic reviews to cite at the time of the design of the new trial. It is therefore possible that the prevalence of failure to consider relevant research may be overstated slightly. However, previous studies have attempted to identify similar studies \[[@CR11]\] but have found broadly similar rates of isolated reports. Furthermore, the present study was limited to a restricted time period and few sources. The search strategy looked specifically for protocols in the title and therefore it is possible that a number of trial protocols might have been overlooked. However, the journals included are likely to represent best practice in terms of protocol design and reporting as most of them endorse SPIRIT guidelines with the majority of trial protocols likely remaining unpublished at this juncture. It is therefore likely that the prevalence of failure to identify relevant related research found in the present study represents a best-case scenario. Finally, a limited number of pharmacological studies were identified over the study period; further research focusing on the protocol reporting characteristics for these studies, in particular, would therefore be welcome.

Conclusions {#Sec8}
===========

A relatively high percentage of protocols of randomised trials involves prior citation of either randomised trials, systematic reviews or both. Overall, 41% of protocols involved citation of a systematic review or a randomised trial that was used to inform trial design.

Additional file {#Sec9}
===============

Additional file 1:Data extraction file with raw data. (XLSX 31 kb)

Not applicable.

Funding {#FPar1}
=======

The authors have not received funding to undertake this research.

Availability of data and materials {#FPar2}
==================================

Available with submission.

Authors' contributions {#FPar3}
======================

SH conceived the study, conducted the search, performed data extraction, and edited the manuscript for intellectual content. NP selected the abstracts, performed data extraction, created data tabulations, and edited the manuscript for intellectual content. DK performed data extraction, created data tabulations, and edited the manuscript for intellectual content. PF extracted data, prepared the first manuscript draft, and edited the manuscript for intellectual content. All authors read and approved the final manuscript.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Consent for publication {#FPar5}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar6}
==========================================

Not applicable.
